HUP0301884A2 - Szubsztituált 1-amino-5-fenil-pentán-3-ol- és/vagy 1-amino-6-fenil-hexán-3-ol-származékok gyógyszerként történż alkalmazása - Google Patents
Szubsztituált 1-amino-5-fenil-pentán-3-ol- és/vagy 1-amino-6-fenil-hexán-3-ol-származékok gyógyszerként történż alkalmazásaInfo
- Publication number
- HUP0301884A2 HUP0301884A2 HU0301884A HUP0301884A HUP0301884A2 HU P0301884 A2 HUP0301884 A2 HU P0301884A2 HU 0301884 A HU0301884 A HU 0301884A HU P0301884 A HUP0301884 A HU P0301884A HU P0301884 A2 HUP0301884 A2 HU P0301884A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- optionally substituted
- atom
- amino
- substituted aryl
- Prior art date
Links
- MQRVXBDFCCKLST-UHFFFAOYSA-N 1-amino-5-phenylpentan-3-ol Chemical class NCCC(O)CCC1=CC=CC=C1 MQRVXBDFCCKLST-UHFFFAOYSA-N 0.000 title abstract 2
- LKVTZBZZXGPMIC-UHFFFAOYSA-N 1-amino-6-phenylhexan-3-ol Chemical class NCCC(O)CCCC1=CC=CC=C1 LKVTZBZZXGPMIC-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány (I) általános képletű szubszttuált 1-amino-5-fenil-pentán-3-ol- és/vagy 1-amino-6-fenil-hexán-3-ol-származékok, ezekdiasztereomerjei, enantiomerjei és fiziológiailag alkalmazható sóialkalmazására vonatkozik NMDA antagonista hatással rendelkezőgyógyszerkészítmény előállítására, a képletben n értéke 1 vagy 2 Ajelentése adott esetben szubsztituált aril- vagy heteroarilcsoport, R1és R2 jelentése egymástól függetlenül 1-6 szénatomos alkilcsoport vagyR1 és R2 jelentése együtt -(CH2)2-6- képletű csoport, amely adottesetben fenilcsoporttal szubsztituálva vagy benzokondenzálva lehet, R3és R4 jelentése egymástól függetlenül 1-6 szénatomos alkilcsoport,adott esetben szubsztituált arilcsoport vagy 1-3 szénatomosalkilénláncon keresztül kapcsolódó és adott esetben szubsztituáltarilcsoport, vagy R3 és R4 jelentése együtt -(CH2)3-6- vagy -CH2CH2OCH2CH2- képletű csoport, R5, R6 és R7 jelentése egymástólfüggetlenül hidrogénatom, fluoratom, klóratom, brómatom, jódatom,trifluormetilcsoport, -OR8, -SO2CH3 vagy -SO2CF3 képletű csoport,fenilcsoport; cianocsoport, nitrocsoport vagy 1-6 szénatorsosalkilcsoport, R8 jelentése hidrogénatom; 1-6 szénatomos alkilcsoport,adott esetben szubsztituált arilcsoport, adott esetben szubsztituáltheteroarilcsoport vagy 1-3 szénatomos alkilénláncon keresztülkapcsolódó és adott esetben szubsztituált aril- vagyheteroarilcsoport. A vegyületek többek között gutaütés, epilepszia,skizofrénia neurodegeneratív betegségek, elsősorban Alzheimer-kór vagyParkinson-kór kezelésére alkalamasak. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10025238A DE10025238A1 (de) | 2000-05-22 | 2000-05-22 | Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel |
| PCT/EP2001/005349 WO2001089505A1 (de) | 2000-05-22 | 2001-05-10 | Verwendung substituierter 1-amino-5-phenylpentan-3-ol- und/oder 1-amino-6-phenylheyan-3-ol-verbindungen als arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0301884A2 true HUP0301884A2 (hu) | 2003-09-29 |
Family
ID=7643080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0301884A HUP0301884A2 (hu) | 2000-05-22 | 2001-05-10 | Szubsztituált 1-amino-5-fenil-pentán-3-ol- és/vagy 1-amino-6-fenil-hexán-3-ol-származékok gyógyszerként történż alkalmazása |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6784175B2 (hu) |
| EP (1) | EP1289514B1 (hu) |
| JP (1) | JP2004509842A (hu) |
| AR (1) | AR029091A1 (hu) |
| AT (1) | ATE281158T1 (hu) |
| AU (2) | AU7402201A (hu) |
| CA (1) | CA2406198A1 (hu) |
| DE (2) | DE10025238A1 (hu) |
| ES (1) | ES2231502T3 (hu) |
| HU (1) | HUP0301884A2 (hu) |
| MX (1) | MXPA02011410A (hu) |
| NZ (1) | NZ521439A (hu) |
| PE (1) | PE20011261A1 (hu) |
| PT (1) | PT1289514E (hu) |
| UY (1) | UY26718A1 (hu) |
| WO (1) | WO2001089505A1 (hu) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6856700B1 (en) * | 2000-05-24 | 2005-02-15 | Microsoft Corporation | Palettized image compression |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US8268866B2 (en) | 2004-03-29 | 2012-09-18 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| US9072662B2 (en) | 2004-03-29 | 2015-07-07 | Auris Medical Ag | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| SI1928405T1 (sl) * | 2005-09-28 | 2014-12-31 | Auris Medical Ag | Farmacevtski sestavki za zdravljenje motenj notranjega ušesa |
| WO2012009258A2 (en) * | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| US20150044200A1 (en) | 2011-12-12 | 2015-02-12 | Otolanum Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4017637A (en) | 1973-03-26 | 1977-04-12 | American Home Products Corporation | Benzylamine analgesics |
| US4155935A (en) * | 1973-03-26 | 1979-05-22 | American Home Products Corporation | Benzylamine analgesics |
| US4366172A (en) * | 1977-09-29 | 1982-12-28 | The Upjohn Company | 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use |
| IE913279A1 (en) | 1990-09-26 | 1992-04-08 | Astra Ab | (2-Thienyl)alkylamine Derivatives Having Neuroprotective¹Properties |
| DE19915601A1 (de) * | 1999-04-07 | 2000-10-19 | Gruenenthal Gmbh | 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung |
-
2000
- 2000-05-22 DE DE10025238A patent/DE10025238A1/de not_active Withdrawn
-
2001
- 2001-05-10 EP EP01940450A patent/EP1289514B1/de not_active Expired - Lifetime
- 2001-05-10 US US10/276,617 patent/US6784175B2/en not_active Expired - Fee Related
- 2001-05-10 ES ES01940450T patent/ES2231502T3/es not_active Expired - Lifetime
- 2001-05-10 AU AU7402201A patent/AU7402201A/xx active Pending
- 2001-05-10 AT AT01940450T patent/ATE281158T1/de not_active IP Right Cessation
- 2001-05-10 WO PCT/EP2001/005349 patent/WO2001089505A1/de active IP Right Grant
- 2001-05-10 HU HU0301884A patent/HUP0301884A2/hu unknown
- 2001-05-10 JP JP2001585750A patent/JP2004509842A/ja active Pending
- 2001-05-10 NZ NZ521439A patent/NZ521439A/en unknown
- 2001-05-10 AU AU2001274022A patent/AU2001274022B2/en not_active Ceased
- 2001-05-10 PT PT01940450T patent/PT1289514E/pt unknown
- 2001-05-10 DE DE50104405T patent/DE50104405D1/de not_active Expired - Fee Related
- 2001-05-10 CA CA002406198A patent/CA2406198A1/en not_active Abandoned
- 2001-05-10 MX MXPA02011410A patent/MXPA02011410A/es active IP Right Grant
- 2001-05-17 AR ARP010102344A patent/AR029091A1/es not_active Application Discontinuation
- 2001-05-18 UY UY26718A patent/UY26718A1/es not_active Application Discontinuation
- 2001-05-21 PE PE2001000456A patent/PE20011261A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1289514B1 (de) | 2004-11-03 |
| DE10025238A1 (de) | 2001-11-29 |
| DE50104405D1 (de) | 2004-12-09 |
| MXPA02011410A (es) | 2003-06-06 |
| UY26718A1 (es) | 2001-06-29 |
| US20030181450A1 (en) | 2003-09-25 |
| AU2001274022B2 (en) | 2004-10-14 |
| ES2231502T3 (es) | 2005-05-16 |
| PE20011261A1 (es) | 2002-01-26 |
| ATE281158T1 (de) | 2004-11-15 |
| WO2001089505A1 (de) | 2001-11-29 |
| NZ521439A (en) | 2005-06-24 |
| AR029091A1 (es) | 2003-06-04 |
| CA2406198A1 (en) | 2002-10-16 |
| PT1289514E (pt) | 2005-02-28 |
| EP1289514A1 (de) | 2003-03-12 |
| US6784175B2 (en) | 2004-08-31 |
| AU7402201A (en) | 2001-12-03 |
| JP2004509842A (ja) | 2004-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
| HUP0301745A2 (hu) | Ciklopentánindolok, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása | |
| TW200508180A (en) | Therapeutic agents | |
| TW200505907A (en) | Piperidine-benzenesulfonamide derivatives | |
| NO994452D0 (no) | Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse | |
| HUP0001607A2 (hu) | Tienopirimidinszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás ezek előállítására, valamint e vegyületek alkalmazása | |
| HUP0204245A2 (hu) | Új N-aza-biciklo-amid-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0402507A2 (hu) | N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| CY1106276T1 (el) | Παραγωγα υποκατεστημενου φαινυλπροπιονικου οξεος ως ανταγωνιστες σε υποδοχεις αλφα που ενepγοποιουνται απο παραγοντες που επαγουν τον πολλαπλασιασμο των ανθρωπινων υπepοξεισωματων (ppar) | |
| HUP0401889A2 (hu) | 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0400206A2 (hu) | Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0300029A2 (en) | Adenosine receptor modulators, pharmaceutical compositions containing them and their use | |
| SE9600683D0 (sv) | Azabicyclic esters of carbamic acids useful in therapy | |
| WO2002008219A3 (en) | 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission | |
| DE50310161D1 (de) | Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
| TW200605894A (en) | Arylsulfonyl benzodioxanes and methods of use the same | |
| HUP0401211A2 (hu) | Helyettesített pirazolo-pirimidinek és tiazolo-pirimidinek, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP0401883A2 (hu) | Muszkarin agonisták és ezeket tartalmazó gyógyászati készítmények | |
| HUP0302115A2 (hu) | Tiazabiciklo[3.2.2]nonán-fenil-izoxazol-származékok, előállításuk és ezeket tartalamzó gyógyszerkészítmények | |
| HUP0301884A2 (hu) | Szubsztituált 1-amino-5-fenil-pentán-3-ol- és/vagy 1-amino-6-fenil-hexán-3-ol-származékok gyógyszerként történż alkalmazása | |
| HUP0001093A2 (hu) | 5-HT2A-antagonista oxazolidinon-származékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| HUP0303236A2 (hu) | Karbamátszármazékok alkalmazása fájdalomcsillapításra | |
| MXPA05012368A (es) | Derivados de amidas del acido 2,3,4,5-tetrahidrobenzo[f] [1,4]oxazepina-5-carboxilico como inhibidores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer. | |
| HUP0302616A2 (hu) | Triptaminszármazékok és analóg vegyületek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |